IL17A and chronic obstructive pulmonary disease: In addition, the magnitude of the reduction in sputum IL-17A concentrations was significant in patients with COPD treated with simvastatin compared with control subjects receiving placebo (mean difference, −16.4 pg/mL; 95% CI, −28.3 to −4.4; P = .01) (Fig 2A, Table 3).